August 25, 2015 | Biologics, physicians, rheumatoid arthritis
HCPs predict the future of the biologics market
Findings from a recent survey of physicians across Europe has revealed that, despite stiff competition from newer biologics, biosimilars and pipeline agents, physicians expect current market leaders Enbrel (etanercept) and Humira (adalimumab) to continue to lead the market and be used to treat over a third of Rheumatoid Arthritis (RA) patients in three years’ time. Nevertheless, the anti-TNF segment is predicted to experience a strong downturn with a 19% loss in share in the same period.
Download our RA Perceptions: Predicting the future of the European market infographic now »
RA Perceptions is a market research study which is carried out every month amongst a panel of 200 physicians across five European countries (France, Germany, Italy, Spain and the UK) and asks physicians about current and future perceptions of the RA market. These findings are from the June survey. RA Perceptions is a component of a larger ongoing patient tracking study called Therapy Watch RA, conducted by global healthcare market research specialist Research Partnership. An infographic highlights the key findings from the study.
Biologic agents with novel mechanisms of action (such as Roche’s RoActemra) are expected to outperform the overall EU biologics market with 15% growth over the next 3 years.
Biosimilars (the approved follow-on products to innovator biologics) will benefit from the greatest gains. Physicians predict a four-fold increase in their use of Hospira’s Inflectra and Celltrion’s Remsima. Despite heavy discounting of some biosimilars in certain markets such as France, the overall market share for these infliximab biosimilars is projected to remain relatively small. Less than 25% of physicians currently report prescribing biosimilars.
Overall, physicians’ awareness of pipeline agents in RA is low. The greatest levels of familiarity and interest were reported for novel small molecules such as Celgene’s Otezla (apremilast) and Pfizer’s Xeljanz (tofacitinib), which both offer a new oral alternative for patients who fail to respond adequately or are intolerant to traditional disease modifying treatments. Of the physicians who were familiar with these agents, 89% said they would prescribe Otezla and 83% stated they would prescribe Xeljanz, in the next 3 years.
The RA biologics market is expected to undergo significant changes in the next few years as newer entrants compete with established brands and biosimilars become increasingly accepted for use as cheaper alternatives to the branded biologics.
This content was provided by Inizio
Latest Content from Inizio
Head of Therapy Watch, Helen Parfitt and Head of Living With, Mariel Metcalfe, investigate Lupus from the perspective of both healthcare professionals and patients using data from our syndicated products.
Evoke KYNE took home the Communiqué Communications Consultancy of the Year award at the 2021 Communiqué Awards held on 1 September at the Grosvenor House hotel in London.David Kyne, CEO, Evoke KYNE said:…
February 8, 2022 – Michael Grela, Evoke KYNE’s EVP, Head of Reputation and Social Impact, has been elected President of the Society for Health Communication, a member-driven organization working to advance the science…
New York, April 27, 2022 – Evoke KYNE, an award-winning health communications agency, today announced the appointment of Maureen Byrne to President. Byrne will assume global leadership responsibilities from David Kyne including management of its…
Janet Powers has joined the company as a Director in the MedTech division.
Headed up by Research Director, Angela McMean, the Evoke Mind+Matter Insights division comprises a team of primary research specialists focused on delivering meaningful, data-driven insight that supports the agency’s mission…
Download our curated collection of case studies and other useful resources that illustrate how we apply the principles of behavioural science in our research design.
In this 45-minute session, Head of Living With, Mariel Metcalfe spoke to Brenda, who was diagnosed with Lupus 12 years ago.
Find out how a study design which better reflects real-world choices can produce a more realistic model for the future market.
Download this white paper, in which we look at how market access and hospital processes will need to transform to accommodate the the influx of CAR-T therapies
